Skip to main content
. 2023 Jul 22;15:118. doi: 10.1186/s13148-023-01535-4

Fig. 4.

Fig. 4

Circulating NPTX2 methylation status as prognostic biomarker in mPDAC patients. A Overall survival (OS) according to plasma RAS mutant allele fraction (MAF). B Progression-free survival (PFS) according to plasma RAS MAF. C OS according to CA19-9 level. D PFS according to CA19-9 level. E OS according to cfDNA concentration. F PFS according to cfDNA concentration. G OS according to NPTX2 methylation. H PFS according to NPTX2 methylation